Oncology Medical News about Imatinib, GI stromal tumors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: The intergroup EORTC-ISG-AGITG phase III trial
Journal of Clinical Oncology, 08/24/09

Cesne AL et al. - Study reports that RECIST (Response Evaluation Criteria in Solid Tumors), perfectly enables early discrimination between patients who benefited long term from imatinib and those who did not. After 6 months of imatinib, if the patient is not experiencing progressive disease (PD), the pattern of radiologic response by tumor size criteria has no prognostic value for further outcome.

Methods

An investigation of whether the response classification assessed by RECIST predicts for time to progression (TTP) and overall survival (OS)
Per protocol, the first 3 disease assessments were done at 2, 4, and 6 mo
For the purpose of the analysis, disease response was subclassified in 6 categories:
- Partial response (PR; > 30% size reduction)
- Minor response (MR; 10% to 30% reduction)
- No change as either NC- (0% to 10% reduction) or NC+ (0% to 20% size increase)
- Progressive disease (PD; > 20% increase/new lesions), and
- Subjective PD (clinical progression)

Results

906 pts had measurable disease at entry
At all measurement time points, CR, PR, and MR resulted in similar TTP and OS
This was also true for NC– and NC+, and for PD and subjective PD
Pts were subsequently classified as responders (CR/PR/MR), NC (NC+/NC–), or PD
This 3-class response categorization was found to be highly predictive of further progression or survival for the first 2 measurement points
After 6 mo of imatinib, responders (CR/PR/MR) had the same survival prognosis as pts classified as NC

<< Previous
Role of anthracyclines in the treatment of early breast cancer

Next >>
Standard graft-versus-host disease prophylaxis with or without...